Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M; REAL Study Group. Komano Y, et al. Among authors: hashiramoto a. J Rheumatol. 2011 Jul;38(7):1258-64. doi: 10.3899/jrheum.101009. Epub 2011 Apr 15. J Rheumatol. 2011. PMID: 21498482
Prospective study of methotrexate treatment for rheumatoid arthritis treated legitimately according to the government recommended 8 mg/week dose.
Hashiramoto A, Shiozawa K, Tanaka Y, Yamane T, Murata M, Tanaka C, Terashima Y, Koyama K, Nakagawa N, Abe S, Yoshihara R, Saegusa Y, Tsumiyama K, Komai K, Sakai Y, Shiozawa S. Hashiramoto A, et al. Mod Rheumatol. 2009;19(6):637-42. doi: 10.1007/s10165-009-0205-x. Epub 2009 Jul 22. Mod Rheumatol. 2009. PMID: 19626390
Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis.
Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, Amano K, Nakajima A, Atsumi T, Koike T, Ihata A, Ishigatsubo Y, Saito K, Tanaka Y, Ito S, Sumida T, Tohma S, Tamura N, Fujii T, Sugihara T, Kawakami A, Hagino N, Ueki Y, Hashiramoto A, Nagasaka K, Miyasaka N, Harigai M; Real Study Group. Sakai R, et al. Among authors: hashiramoto a. Arthritis Care Res (Hoboken). 2012 Aug;64(8):1125-34. doi: 10.1002/acr.21666. Arthritis Care Res (Hoboken). 2012. PMID: 22422487 Free article.
Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.
Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R, Nagasawa H, Amano K, Saito K, Tanaka Y, Ito S, Sumida T, Ihata A, Ishigatsubo Y, Atsumi T, Koike T, Nakajima A, Tamura N, Fujii T, Dobashi H, Tohma S, Sugihara T, Ueki Y, Hashiramoto A, Kawakami A, Hagino N, Miyasaka N, Harigai M; REAL Study Group. Sakai R, et al. Among authors: hashiramoto a. Ann Rheum Dis. 2012 Nov;71(11):1820-6. doi: 10.1136/annrheumdis-2011-200838. Epub 2012 Apr 13. Ann Rheum Dis. 2012. PMID: 22504558 Free article.
The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database.
Sakai R, Cho SK, Nanki T, Koike R, Watanabe K, Yamazaki H, Nagasawa H, Amano K, Tanaka Y, Sumida T, Ihata A, Yasuda S, Nakajima A, Sugihara T, Tamura N, Fujii T, Dobashi H, Miura Y, Miyasaka N, Harigai M; REAL study group. Sakai R, et al. Rheumatol Int. 2014 Dec;34(12):1729-36. doi: 10.1007/s00296-014-3045-8. Epub 2014 May 23. Rheumatol Int. 2014. PMID: 24852650
76 results